The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•6 March 2026•

1 min read

uniQure Shares Plunge 32% After FDA Rejects Early Data for Huntington’s Treatment

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1uniQure (QURE) stock plummeted 32% within a single week.

2The FDA stated that AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.

Shares of uniQure (QURE) experienced a significant sell-off this week, plummeting 32% following a major regulatory setback. The U.S. Food and Drug Administration (FDA) informed the company that current data from Phase I/II trials of its AMT-130 gene therapy are insufficient to support a marketing application. This candidate, aimed at treating Huntington's disease, was a key asset in the company's pipeline, making the regulator's feedback a substantial blow to growth prospects. The FDA's stance implies that additional clinical evidence will be required, significantly delaying the potential path to market. Investors reacted sharply to the news, wiping out a substantial portion of the company's market capitalization in a single week. This development underscores the high risks inherent in the biotech sector and its heavy reliance on regulatory milestones.